MY131426A - Hematopoietic arabinogalactan composition - Google Patents
Hematopoietic arabinogalactan compositionInfo
- Publication number
- MY131426A MY131426A MYPI20003006A MYPI20003006A MY131426A MY 131426 A MY131426 A MY 131426A MY PI20003006 A MYPI20003006 A MY PI20003006A MY PI20003006 A MYPI20003006 A MY PI20003006A MY 131426 A MY131426 A MY 131426A
- Authority
- MY
- Malaysia
- Prior art keywords
- stimulating
- exposure
- arabinogalactan
- compositions
- csf
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 4
- SATHPVQTSSUFFW-UHFFFAOYSA-N 4-[6-[(3,5-dihydroxy-4-methoxyoxan-2-yl)oxymethyl]-3,5-dihydroxy-4-methoxyoxan-2-yl]oxy-2-(hydroxymethyl)-6-methyloxane-3,5-diol Chemical compound OC1C(OC)C(O)COC1OCC1C(O)C(OC)C(O)C(OC2C(C(CO)OC(C)C2O)O)O1 SATHPVQTSSUFFW-UHFFFAOYSA-N 0.000 title abstract 3
- 229920000189 Arabinogalactan Polymers 0.000 title abstract 3
- 239000001904 Arabinogalactan Substances 0.000 title abstract 3
- 235000019312 arabinogalactan Nutrition 0.000 title abstract 3
- 230000003394 haemopoietic effect Effects 0.000 title 1
- 230000004936 stimulating effect Effects 0.000 abstract 3
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 abstract 1
- 206010006895 Cachexia Diseases 0.000 abstract 1
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 abstract 1
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 abstract 1
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 abstract 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 abstract 1
- -1 IFN-У Proteins 0.000 abstract 1
- 108090001005 Interleukin-6 Proteins 0.000 abstract 1
- 241000124008 Mammalia Species 0.000 abstract 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 abstract 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 abstract 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 abstract 1
- 206010047700 Vomiting Diseases 0.000 abstract 1
- 208000007502 anemia Diseases 0.000 abstract 1
- 108010054251 arabinogalactan proteins Proteins 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 230000011132 hemopoiesis Effects 0.000 abstract 1
- 208000006454 hepatitis Diseases 0.000 abstract 1
- 231100000283 hepatitis Toxicity 0.000 abstract 1
- 210000003494 hepatocyte Anatomy 0.000 abstract 1
- 230000001939 inductive effect Effects 0.000 abstract 1
- 239000007972 injectable composition Substances 0.000 abstract 1
- 230000035800 maturation Effects 0.000 abstract 1
- 210000003593 megakaryocyte Anatomy 0.000 abstract 1
- 208000004235 neutropenia Diseases 0.000 abstract 1
- 210000000440 neutrophil Anatomy 0.000 abstract 1
- 230000035755 proliferation Effects 0.000 abstract 1
- 230000005855 radiation Effects 0.000 abstract 1
- 238000011084 recovery Methods 0.000 abstract 1
- 206010043554 thrombocytopenia Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Medical Informatics (AREA)
- Materials Engineering (AREA)
- Polymers & Plastics (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
PURIFIED ARABINOGALACTAN COMPOSITIONS ISOLATED FROM THE ROOTS OF ASTAGALUS MEMBRANACEUS, AND ARABINOGALACTAN PROTEIN COMPOSITIONS HAVING A WEIGHT AVERAGE MOLECULAR WEIGHT OF AT LEAST 100 KILODALTONS ISOLATED FROM THESE PURIFIED ARABINOGALACTAN COMPOSITIONS, ARE CAPABLE OF RECONSTITUTION INTO AQUEOUS INTRAVENOUSLY INJECTABLE FORMULATIONS; AND ARE USEFUL FOR STIMULATING HEMA TOPOIESIS, INDUCING THE PROLIFERATION OR MATURATION OF MEGAKARYOCYTES, STIMULATING THE PRODUCTION OF IL-Iβ, IL-6, TNF-α, IFN-У, GM-CSF, OR G-CSF, STIMULATING THE PRODUCTION OR ACTION OF NEUTROPHILS, TREATING NEUTROPENIA, ANEMIA, OR THROMBOCYTOPENIA, ACCELERATING RECOVERY FROM EXPOSURE (E.G. ACCIDENTAL OR NON-THERAPEUTIC EXPOSURE, ASWELL AS THERPEUTIC EXPOSURE) TO CYTOTOXIS AGENTS OR RADIATION, TREATING CACHEXIA, EMESIS, OR DRUG WITHDRAWAL SYSMTOMS, OR MODIFYING BIOLOGICAL RESPONSES OR PROTECTING HEPATIC CELLS IN HEPATITIS B, IN AMAMMAL WHEN INTRAVENOUSLY ADMINISTERED TO THE MAMMAL.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US14203199P | 1999-06-30 | 1999-06-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MY131426A true MY131426A (en) | 2007-08-30 |
Family
ID=22498290
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MYPI20003006A MY131426A (en) | 1999-06-30 | 2000-06-30 | Hematopoietic arabinogalactan composition |
Country Status (7)
| Country | Link |
|---|---|
| EP (1) | EP1200482A1 (en) |
| CN (1) | CN1179979C (en) |
| AU (1) | AU6203600A (en) |
| HK (1) | HK1046290B (en) |
| MY (1) | MY131426A (en) |
| TW (1) | TWI240629B (en) |
| WO (1) | WO2001000682A1 (en) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2001271675A1 (en) | 2000-06-29 | 2002-01-14 | Pharmagenesis, Inc. | Acid-modified arabinogalactan protein composition |
| RU2208440C2 (en) * | 2001-07-20 | 2003-07-20 | Иркутский институт химии им. А.Е. Фаворского СО РАН | Agent eliciting antianemic and immunomodulating activity |
| US7601368B2 (en) | 2004-09-01 | 2009-10-13 | Lupin Limited | Purified Arabinogalactan-Protein (AGP) composition useful in the treatment psoriasis and other disorders |
| CN1854158B (en) * | 2005-04-25 | 2011-09-07 | 蒋来高 | Extraction of astragalus mongholicus polysaccharose by super-critical fluid technology |
| US8137710B2 (en) | 2008-12-15 | 2012-03-20 | EcoPharm Corporation | Treating idiopathic thrombocytopenic purpura with comprising extracts of Astragalus membranaceus |
| EP3191110A4 (en) * | 2014-08-18 | 2018-04-18 | Pharmagenesis, Inc. | Polygalacturonan rhamnogalacturonan1 (pgrg1) composition |
| CN104147254A (en) * | 2014-08-21 | 2014-11-19 | 陈勇 | Traditional Chinese medicine preparation for treating leucocytopenia after chemotherapy |
| CN109432242A (en) * | 2018-11-07 | 2019-03-08 | 郑毅男 | A kind of larch arabinogalactan preparation method and its application in terms of medical treatment |
| CN110551230B (en) * | 2019-09-21 | 2022-02-15 | 天津赛诺制药有限公司 | Preparation method of astragalus polysaccharide |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5589591A (en) * | 1986-07-03 | 1996-12-31 | Advanced Magnetics, Inc. | Endotoxin-free polysaccharides |
| US4944946A (en) * | 1987-01-27 | 1990-07-31 | Yaguang Liu | Pharmaceutical composition for inhibiting viruses and increasing immune function (PII) |
| CN1027168C (en) * | 1989-05-13 | 1994-12-28 | 储大同 | Method for extracting effective components of astragalus membranaceus |
| IT1238685B (en) * | 1990-02-09 | 1993-09-01 | Indena Spa | IMMUNOMODULATING ACTION POLYSACCHARIDES FROM ASTRAGALUS MEMBRANACEOUS AND PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM |
| US5116969B1 (en) * | 1990-04-26 | 1997-04-01 | Larex International Inc | Ultrarefined arabinogalactan product |
| ES2049561B1 (en) * | 1991-04-27 | 1994-12-16 | Andromaco Lab | PROCEDURE FOR OBTAINING POLYMERS WITH ACTIVITY ON THE HEMATOPOYETIC SYSTEM. |
| US5770217A (en) * | 1997-07-02 | 1998-06-23 | Atlatl, Inc. | Dietary supplement for hematological, immune and appetite enhancement |
-
2000
- 2000-06-30 HK HK02107822.7A patent/HK1046290B/en not_active IP Right Cessation
- 2000-06-30 EP EP00948559A patent/EP1200482A1/en not_active Withdrawn
- 2000-06-30 CN CNB008115478A patent/CN1179979C/en not_active Expired - Lifetime
- 2000-06-30 TW TW089112971A patent/TWI240629B/en not_active IP Right Cessation
- 2000-06-30 WO PCT/US2000/018180 patent/WO2001000682A1/en not_active Ceased
- 2000-06-30 AU AU62036/00A patent/AU6203600A/en not_active Abandoned
- 2000-06-30 MY MYPI20003006A patent/MY131426A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN1179979C (en) | 2004-12-15 |
| EP1200482A1 (en) | 2002-05-02 |
| TWI240629B (en) | 2005-10-01 |
| WO2001000682A1 (en) | 2001-01-04 |
| CN1368979A (en) | 2002-09-11 |
| HK1046290B (en) | 2005-08-12 |
| HK1046290A1 (en) | 2003-01-03 |
| AU6203600A (en) | 2001-01-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL85523A (en) | Stable alpha interferon complex,its preparation and pharmaceutical compositions comprising it | |
| JP2003519478A5 (en) | ||
| NO20034492D0 (en) | HSA-free formulations of Interferon <beta> | |
| NZ516664A (en) | Formulations and compositions for interleukin-11 | |
| TW221378B (en) | ||
| CA2387058A1 (en) | Injection vehicle for polymer-based formulations | |
| ES2026469T3 (en) | PREPARATION PROCEDURE OF AN EROSIONABLE AND MOLDABLE COMPOSITION BY INJECTION. | |
| PL316942A1 (en) | Novel pharmaceutic compositions based on taxoides | |
| AU5118990A (en) | Compositions for the sustained-release of chlorhexidine | |
| MY131426A (en) | Hematopoietic arabinogalactan composition | |
| DE69307977D1 (en) | Stabilized derivatives of pharmaceutical compositions containing vitamin D2 and D3 | |
| AP2001002302A0 (en) | 13-Methyl erythromycin derivatives. | |
| GEP20033079B (en) | Pharmaceutical Compositions for Treatment of Diseases Caused by Estrogens Deficiency | |
| MY137547A (en) | Acid-modified arabinogalactan protein composition | |
| IL102814A0 (en) | Pyrazine derivatives,their preparation and pharmaceutical compositions comprising them | |
| IL155788A (en) | Composition comprising biologically active ifn--beta and highly purified mannitol, a method of producing a formulation of biologically active ifn-beta having improved stability and a method for increasing the stability of biologically active ifn-beta in a composition | |
| IL100162A0 (en) | Oral pharmaceutical composition containing cyclosporin and its preparation | |
| KR900700124A (en) | Therapeutic Compositions of IL-2 and DTIC for Treatment of Melanoma | |
| WO1996001634B1 (en) | Long-acting oxytetracycline composition | |
| ES2105923B1 (en) | COMPOSITIONS FOR THE TREATMENT OF AN INFECTION AND DISEASE CAUSED BY THE HEPATITIS B (HBV) VIRUS. | |
| DK0524696T3 (en) | Oral preparations containing dapiprazole | |
| IT1204778B (en) | INJECTABLE PHARMACEUTICAL FORMULATIONS OF ACTIVE INGREDIENTS FOR GENERAL ANESTHETIC ACTIVITIES | |
| FR2701952B1 (en) | New cyclopeptide derivatives of angiopeptin, their preparation process and the pharmaceutical compositions containing them. | |
| EP0458949B1 (en) | Stabilization of k1k2p pro | |
| PL353453A1 (en) | Ascididemin derivatives and their therapeutic applications |